Community Based Strategies for Early Detection of Melanoma

A Pilot Feasibility Study of Community Based Strategies for Early Detection of Melanoma

The purpose of this study is to pilot the use of community education and digital dermatology to increase the early detection of curable melanomas.

Study Overview

• Status: Not yet recruiting
• Conditions: Melanoma
• Intervention / Treatment: Behavioral: Community Based Strategies for Early Detection of Melanoma

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Hayden Hutchison, MSW, MPH; Phone Number: 310-423-2361; Email: hayden.hutchison@cshs.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

200 melanoma survivors drawn from the California Cancer Registry will be invited to participate in the study. Assuming a 20% response rate, approximately 40 individuals will be identified to participate in the study, including 20 in Southern California and 20 in Northern California. Participants will be invited to identify up to four friends or first-degree family members to also participate in the study, for a total of 200 participants.

Description

Inclusion Criteria:

• 18 years and older
• >1mm lesion thickness with ulceration (T2b) or >2mm lesion thickness (T3/T4)
• Low socioeconomic status (SES) Non-Latinx White individuals (according to Yost's index SES level based on a principal components analysis)
• Latinx individuals
• Individual resides in semi-rural area, including zip codes within Antelope Valley in Southern California and Salinas in Northern California
• Individual speaks and reads English or Spanish
• Voluntary willingness and comprehension to consent

Exclusion Criteria:

Exclusion criteria is stage 0, I, IV, or unstaged diagnosis, or any individual who does not meet the above stated eligibility criteria will be excluded from the study.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Completion of self and partner skin examinations	Proportion of individuals recruited to those that follow through with the protocol	3 months
Completion of self and partner skin examinations	Proportion of individuals recruited to those that follow through with the protocol	6 months

Collaborators and Investigators

• Sponsor: Cedars-Sinai Medical Center
• Collaborators: Stanford University
• Investigators: Principal Investigator: Robert Haile, DrPH, MPH, Cedars-Sinai

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2024
• Primary Completion (Estimated): January 31, 2025
• Study Completion (Estimated): March 1, 2025

Study Registration Dates

• First Submitted: March 9, 2021
• First Submitted That Met QC Criteria: March 11, 2021
• First Posted (Actual): March 16, 2021

Study Record Updates

• Last Update Posted (Actual): August 29, 2023
• Last Update Submitted That Met QC Criteria: August 28, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma
• Other Study ID Numbers: STUDY00001181

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No